Drug intelligence / Profile preview

Levamlodipine

Development stage
Approved
Lead developer
CSPC Ouyi Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Levamlodipine is the pharmacologically active S-enantiomer of amlodipine, a dihydropyridine calcium channel blocker. It is used as an antihypertensive agent to treat high blood pressure in adults and children, either alone or in combination with other medications. Levamlodipine works by selectively inhibiting L-type calcium channels in vascular smooth muscle, leading to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. Its action on cardiac muscle is less pronounced than on vascular smooth muscle. The drug may also decrease coronary vascular resistance and increase coronary blood flow, contributing to its antianginal effects[1][2][3][4][5][6][7]. Levamlodipine is administered orally and undergoes extensive hepatic metabolism; it has a long half-life that supports once-daily dosing.

Brand names
Conjupri
Other names
levamlodipine maleate
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NOS2 (Nitric Oxide Synthase 2)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)STIM1 (Stromal interaction molecule 1)NOS3 (eNOS)

Beyond the preview

Go deeper on Levamlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levamlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call